Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Human Genome Sciences history
Human Genome Sciences company history timeline
Human Genome Sciences was begun in 1992 as a way of funding discoveries made by The Institute for Genomic Research (TIGR), the genomics center founded by J. Craig Venter that pioneered big-scale genomics and sequenced he first genomes.
In order to support and promote these new activities in genome sciences, the Human Genome Research Center was established in 1992 at the Institute of Medical Sciences, the University of Tokyo.
The DNA sequencing laboratory in the Human Genome Research Center at the Institute of Medical Sciences, the University of Tokyo, in 1992.
At the next meeting of HGM at Washington D.C. in October 1994, however, the atmosphere was quite different from the previous meeting in Kobe.
At the meeting, the participants also determined the sequencing share of each country and center, in which Japan, together with Germany, claimed chromosome 21 as its first target based on the international chromosome 21 sequencing consortium established in late 1994.
The international consortium had a meeting in Bermuda in February 1996, in which the important principles called the Bermuda Principles20) for the rapid release of DNA sequence data to the public were proposed and agreed.
However, the scale of the funding was extremely small in comparison with the United States human genome budget, $243 million in fiscal year 1996 and $266 million the following year.
Monbusho launched a new 5-year program “Genome Sciences” (PI: the author) in 1996.
In order to keep up with the phase shift to large-scale sequencing, the RIKEN Genomic Sciences Center was established in Japan in 1998.
Five months later, in May 2000, the second completed chromosome was announced, chromosome 21, which was completed by the chromosome 21 sequencing consortium led by the Japanese and German teams.7) In particular, the RIKEN GSC team played leading roles in the completion.
The completion of the rough draft was announced in June 2000 by Collins and Venter.
A ceremony to celebrate the finishing of the human draft sequence took place in Washington D.C. on June 26, 2000 in the presence of President Bill Clinton with Francis Collins and Craig Venter in attendance.
In 2000, wanting to expand his vision, Doctor Hood left the UW to form his own institute, and other faculty left the department at around the same time.
In 2000, Monbusho and STA were reorganized into the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT), and MEXT started a new 5-year program for genome research promotion (PI: Yuji Kohara) under a Grant-in-Aid for Scientific Research on Priority Areas.
In 2001, the Genome Sciences department was formed.
The last strategy meeting was held at RIKEN GSC in August 2002 (Fig. (Fig.1111).
2002 was a portentous time for both Bob Waterston and the Genome Sciences department.
On April 14, 2003, the international team finally declared the completion of the human genome sequence (https://www.genome.gov/11006929/2003-release-international-consortium-completes-hgp/ and https://www.ddbj.nig.ac.jp/news/ja/wn030423.html).
Prime Minister Jun-ichiro Koizumi and the representatives of the Japanese team (the author and Shimizu) at the cerebration ceremony for the completion of the human genome sequencing at the Kantei (the Prime Minister’s official residence) on April 14, 2003.
In 2006, the 260,000 square foot, $150 million facility was completed.
Benlysta the first drug for lupus, was approved on March 9, 2011.
Sales in 2011 were just $52 million – not an auspicious start.
Some analysts still think it could be a $1 billion seller by 2016.
In Japan, Human Genome Archive activity started in 2016 with support from the Genome Technology Committee of the JSPS and is now in progress.
Rate Human Genome Sciences' efforts to communicate its history to employees.
Human Genome Sciences jobs
Do you work at Human Genome Sciences?
Is Human Genome Sciences' vision a big part of strategic planning?
Human Genome Sciences competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amgen | 1980 | $33.4B | 22,000 | 567 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 689 |
| Regeneron | 1988 | $14.2B | 9,123 | 356 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Seagen | 1997 | $2.0B | 900 | - |
| Merck | 1891 | $64.2B | 74,000 | 1,328 |
| Med Immune Inc | 1988 | $1.7B | 5,000 | - |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 288 |
| 454 Life Sciences | 2005 | $19.4M | 100 | - |
| XOMA | 1981 | $28.5M | 11 | - |
Human Genome Sciences history FAQs
Zippia gives an in-depth look into the details of Human Genome Sciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Human Genome Sciences. The employee data is based on information from people who have self-reported their past or current employments at Human Genome Sciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Human Genome Sciences. The data presented on this page does not represent the view of Human Genome Sciences and its employees or that of Zippia.
Human Genome Sciences may also be known as or be related to HUMAN GENOME SCIENCES INC, Human Genome Sciences and Human Genome Sciences Inc.